Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

FUSION GENE BCR-ABL: FROM ETIOPATHOGENESIS TO THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA

Jurnal kedokteran dan kesehatan Indonesia · Vol. 8 No. 1 (2017) · hlm. 29–37

DOI
10.20885/jkki.vol8.iss1.art5
ISSN
2085-4145, 2527-2950
Terbit
2017-04-26
Penerbit
Islamic University of Indonesia
Bahasa
id
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm. CML is relative frequent disorder. Most of CML patients have Philadelphia chromosome (Ph),which is derived from a reciprocal translocation between chromosome 9 and 22, t(9;22)(q34;ql1), generating the BCRABLfusion gene. In general, there are 3 breakpoint cluster regions in BCR gene: mayor(M-bcr), minor (m-bcr) and micro (μ-bcr). The BCR-ABL gene encodes proteins that vary in size depending on the breakpoint in the BCR gene. However, these proteins share a high tyrosine kinase activity. In the absence of activating stimuli, BCR-ABL tyrosine kinase able to transferphosphate from ATP (autophosphorilation) to tyrosine residues on various substrates in the cell. It actives intracelluler signaling pathways. These pathways cause increase proliferation or decrease apoptosis and differentiation of a hematopoietic stem cell; and defect in adherence of myeloid progenitors to marrow stroma resulting in CML. These discoveries determined that BCR-ABL fusion gene is critical event in etiopathogenesis of CML and a ideal target for therapy. Therapy of CML patients with BCRABL fusion gene-positif is by block autophosphorilation mechanism by Tyrosine Kinase Inhibitor (TKI), example imatinib. Molecular method to detect BCR-ABL transcript is necessary for monitoring response to TKI in CML pateints.

Kata kunci

Jaringan kolaborasi para penulis

21 penulis · 146 tautan kepenulisan bersama · 31 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Sebelas Maret University
  • RSUD Prof. Dr. Saiful Anwar Malang
  • University of Brawijaya
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Nanang WiyonoSebelas Maret University1
Brian WasitaSebelas Maret University1
Yuyun YueniwatiRSUD Prof. Dr. Saiful Anwar Malang1
Rachmi Fauziah RahayuSebelas Maret University1
Adam FauziUniversity of Brawijaya1
Ratih Dewi YudhaniSebelas Maret University1
Fathimah Afifah ZahrahSebelas Maret University1
Tessa Septian AnugrahSebelas Maret University1
Amelia Tjandra IrawanSebelas Maret University1
Sulistyani KusumaningrumSebelas Maret University1
Muthaminah MuthaminahSebelas Maret University1
Lusi Oka WardhaniSebelas Maret University1
Suyatmi SuyatmiSebelas Maret University1
Kristanto Yuli YarsoSebelas Maret University1
Riza Novierta PesikSebelas Maret University1
Febby Gunawan SiswantoSebelas Maret University1
Muhammad HafizhanSebelas Maret University1
Sri WulandariSebelas Maret University1
Indah AriestaSebelas Maret University1
Muhammad Arif Rahman HakimSebelas Maret University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210214198, pertama di-harvest 20 Nov 2026, terakhir terlihat 20 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="id">FUSION GENE BCR-ABL : FROM ETIOPATHOGENESIS TO THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA</dc:title><dc:creator>Tri Agusti Sholikah</dc:creator><dc:subject>chronic myeloid leukemia</dc:subject><dc:subject>BCR-ABL fusion gene</dc:subject><dc:subject>Philadelphia chromosome</dc:subject><dc:subject>tyrosine kinase activity</dc:subject><dc:subject>autophosphorylation</dc:subject><dc:subject>hematopoietic stem cell proliferation</dc:subject><dc:subject>apoptosis</dc:subject><dc:subject>tyrosine kinase inhibitors</dc:subject><dc:subject>imatinib</dc:subject><dc:subject>treatment response monitoring</dc:subject><dc:description xml:lang="id">Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm. CML is relative frequent disorder. Most of CML patients have Philadelphia chromosome (Ph),which is derived from a reciprocal translocation between chromosome 9 and 22, t(9;22)(q34;ql1), generating the BCRABLfusion gene. In general, there are 3 breakpoint cluster regions in BCR gene : mayor(M-bcr), minor (m-bcr) and micro (μ-bcr). The BCR-ABL gene encodes proteins that vary in size depending on the breakpoint in the BCR gene. However, these proteins share a high tyrosine kinase activity. In the absence of activating stimuli, BCR-ABL tyrosine kinase able to transferphosphate from ATP (autophosphorilation) to tyrosine residues on various substrates in the cell. It actives intracelluler signaling pathways. These pathways cause increase proliferation or decrease apoptosis and differentiation of a hematopoietic stem cell; and defect in adherence of myeloid progenitors to marrow stroma resulting in CML. These discoveries determined that BCR-ABL fusion gene is critical event in etiopathogenesis of CML and a ideal target for therapy. Therapy of CML patients with BCRABL fusion gene-positif is by block autophosphorilation mechanism by Tyrosine Kinase Inhibitor (TKI), example imatinib. Molecular method to detect BCR-ABL transcript is necessary for monitoring response to TKI in CML pateints.</dc:description><dc:publisher>Islamic University of Indonesia</dc:publisher><dc:date>2017-04-26</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://doi.org/10.20885/jkki.vol8.iss1.art5</dc:identifier><dc:identifier>10.20885/jkki.vol8.iss1.art5</dc:identifier><dc:source>Jurnal kedokteran dan kesehatan Indonesia; Vol 8 No 1 (2017); 29-37</dc:source><dc:source>2085-4145</dc:source><dc:source>2527-2950</dc:source><dc:language>id</dc:language><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>